## GOVERNMENT OF INDIA MINISTRY OF CHEMICALS AND FERTILIZERS DEPARTMENT OF PHARMACEUTICALS

## LOK SABHA UNSTARRED QUESTION No. 2839 TO BE ANSWERED ON 17<sup>th</sup> March, 2023

### **Usage of Generic Medicines in Bihar**

#### †2839. SHRI DILESHWAR KAMAIT:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the total quantity of generic medicines used in Bihar during the last three years; and(b) whether the Government has formulated any plan to increase the production as well as
- making generic medicines available at affordable prices in the country?

#### **ANSWER**

# MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI BHAGWANTH KHUBA)

(a): As per information provided by the National Pharmaceutical Pricing Authority, the total sale of medicines by stockists/ dealers to retailers in the country is as under:

Year	Sales Value (in Cr.)
2019-2020	1,44,485.08
2020-2021	1,47,586.41
2021-2022	1,69,234.82
April 2022 - December 2022	1,40,865.31

No separate data, is however, maintained regarding consumption of generic medicines in the country/ specific states, including Bihar.

In order to provide quality generic medicines at affordable prices to all citizens, especially the poor and the deprived ones, *Pradhan Mantri Bhartiya Janaushadhi Pariyojana* (PMBJP) has been launched by the Department of Pharmaceuticals wherein about 9,182 dedicated outlets known as *Pradhan Mantri Bhartiya Janaushadhi Kendras* (PMBJKs) have been opened all across the country till 28.02.2023, out of which 359 Kendras are in the state of Bihar. During last three financial years, total sale of Rs. 19.57 Crore has been made by the Kendras in Bihar.

(b): Department of Pharmaceuticals has taken various steps for increase of production of drugs in the country. In order to encourage domestic manufacturing of pharmaceutical drugs, including generic medicines, two Production Linked Incentive (PLI) schemes have been launched, viz., PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) within an outlay of Rs. 6,940 crores and PLI Scheme for Pharmaceuticals with an outlay of Rs. 15,000 cr. Further, a scheme for providing financial support for creation of Common Infrastructure Facilities (CIFs) in three Bulk Drugs parks in the country has also been approved with a total outlay of Rs. 3,000 cr.

\*\*\*\*